Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
大力的灵雁
zzdai
你嵙这个期刊没买
干净的琦
pluto
张欢馨
微尘
甜豆沙
喷火娃
科研狗
Criminology34
乐空思
GingerF
畔畔
殷勤的紫槐
数据女工
eufhuew
arniu2008
xiaolizi
皖公网安备34019202002308
